Rottlerin inhibits multiple steps involved in insulin-induced glucose uptake in 3T3-L1 adipocytes

Merlijn Bazuine1, Gerard C M van der Zon, Rob van de Ven

  • 1Department of Molecular Cell Biology, Leiden University Medical Center, Wassenaarseweg 72, P.O. Box 9503, 2333 AL Leiden, The Netherlands.

Insights

Rottlerin inhibits insulin-stimulated glucose uptake in adipocytes by reducing GLUT4 transporter movement and directly interfering with glucose transport. This provides new explanations beyond ATP level changes.

Area of Science:

  • Cell biology
  • Biochemistry
  • Metabolism

Background:

  • Rottlerin's effect on glucose uptake and ATP levels in 3T3-L1 adipocytes is debated.
  • Conflicting reports exist regarding ATP depletion's impact on glucose uptake in muscle and fat cells.

Purpose of the Study:

  • To elucidate the precise mechanism by which rottlerin inhibits insulin-stimulated glucose uptake.
  • To resolve discrepancies concerning rottlerin's effects on ATP levels and glucose transport.

Main Methods:

  • Investigated rottlerin's impact on 2-deoxyglucose (2-DOG) uptake in 3T3-L1 adipocytes.
  • Analyzed the translocation of the GLUT4 glucose transporter to the plasma membrane.
  • Examined the effects on the phosphatidyl-inositol-3' (PI-3') kinase pathway and Cbl tyrosine phosphorylation.
  • Performed kinetic analysis of rottlerin's inhibition of glucose uptake.

Main Results:

  • Rottlerin partially inhibited GLUT4 translocation to the plasma membrane.
  • The PI-3' kinase pathway remained unaffected, but Cbl tyrosine phosphorylation was attenuated.
  • Rottlerin exhibited uncompetitive inhibition of glucose uptake, reducing both K(m(app)) and V(max(app)).

Conclusions:

  • Rottlerin inhibits insulin-stimulated 2-deoxyglucose uptake through multiple mechanisms.
  • Reduced GLUT4 translocation and uncompetitive inhibition of transport are key effects.
  • These findings offer alternative explanations for rottlerin's inhibitory action, independent of ATP level alterations.

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Insulin Secretory Vesicles01:05

Insulin Secretory Vesicles

Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...